Cytomedix
This article was originally published in The Gray Sheet
Executive Summary
Deerfield, Illinois firm raises $14.7 mil in equity financing from Fusion Capital Fund II. Proceeds will go towards "general corporate purposes, acquisitions and other opportunities," according to a release. Cytomedix' current product offering include the Autologel and ProCuren wound healing agents, composed of naturally occurring growth factors. Applications include treatment of diabetic foot ulcers, venous stasis and pressure ulcers. Separately on April 26, the firm raised $2.1 mil. in convertible bond financing, with a potential of raising up to $6.5 mil. Funds will go towards paying off other debt securities, including bridge financing obtained in connection with the January 2001 purchase of assets from Curative Health Services, maker of the ProCuren product